Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
RF/CCP negative, +hand synovitis on exam
Related Questions
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
How would you manage a patient with severe deforming seronegative RA who has failed or been intolerant to DMARDs, TNFi, abatacept, Jak inhibitors, IL-6 and IL-1 agents in addition to Rituxan and moderate dose prednisone?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
Would you switch to a TNF-I if patient developed squamous cell skin cancer on Orencia after failure of MTX for seropositive RA?
Do you use the peri-operative management of biologics and DMARDs guidelines, which were mainly based on total hip and knee replacement surgeries, for all peri-operative surgical management?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
When considering biologic therapy after failure of MTX or triple therapy, do you consider using Abatacept as a first line biologic?